A detailed history of Rhumbline Advisers transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 311,368 shares of CPRX stock, worth $6.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
311,368
Previous 323,769 3.83%
Holding current value
$6.73 Million
Previous $5.02 Million 23.41%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$15.19 - $21.35 $188,371 - $264,761
-12,401 Reduced 3.83%
311,368 $6.19 Million
Q2 2024

Aug 01, 2024

BUY
$14.68 - $16.92 $158,617 - $182,820
10,805 Added 3.45%
323,769 $5.02 Million
Q1 2024

May 09, 2024

BUY
$13.18 - $17.11 $316,886 - $411,375
24,043 Added 8.32%
312,964 $4.99 Million
Q4 2023

Feb 08, 2024

SELL
$11.78 - $17.29 $38,461 - $56,451
-3,265 Reduced 1.12%
288,921 $4.86 Million
Q3 2023

Nov 09, 2023

BUY
$11.69 - $15.02 $54,054 - $69,452
4,624 Added 1.61%
292,186 $3.42 Million
Q2 2023

Aug 08, 2023

BUY
$11.5 - $18.08 $77,981 - $122,600
6,781 Added 2.42%
287,562 $3.86 Million
Q1 2023

May 11, 2023

BUY
$14.34 - $21.05 $235,749 - $346,062
16,440 Added 6.22%
280,781 $4.66 Million
Q4 2022

Feb 14, 2023

BUY
$12.25 - $19.5 $73,990 - $117,780
6,040 Added 2.34%
264,341 $4.92 Million
Q3 2022

Nov 10, 2022

BUY
$7.06 - $15.52 $1.04 Million - $2.29 Million
147,517 Added 133.16%
258,301 $3.31 Million
Q2 2022

Aug 11, 2022

SELL
$6.23 - $8.57 $106,962 - $147,138
-17,169 Reduced 13.42%
110,784 $777,000
Q1 2022

May 12, 2022

SELL
$5.31 - $8.31 $109,014 - $170,604
-20,530 Reduced 13.83%
127,953 $1.06 Million
Q4 2021

Feb 10, 2022

SELL
$5.21 - $7.45 $5,673 - $8,113
-1,089 Reduced 0.73%
148,483 $1.01 Million
Q3 2021

Nov 12, 2021

BUY
$4.85 - $6.04 $10,577 - $13,173
2,181 Added 1.48%
149,572 $793,000
Q2 2021

Aug 05, 2021

BUY
$4.29 - $6.05 $119,455 - $168,462
27,845 Added 23.29%
147,391 $847,000
Q1 2021

May 06, 2021

SELL
$3.45 - $4.69 $23,253 - $31,610
-6,740 Reduced 5.34%
119,546 $551,000
Q4 2020

Feb 10, 2021

BUY
$2.97 - $3.83 $21,176 - $27,307
7,130 Added 5.98%
126,286 $422,000
Q3 2020

Nov 12, 2020

SELL
$2.97 - $5.08 $49,910 - $85,369
-16,805 Reduced 12.36%
119,156 $354,000
Q2 2020

Aug 13, 2020

BUY
$3.48 - $5.05 $33,759 - $48,990
9,701 Added 7.68%
135,961 $628,000
Q1 2020

May 06, 2020

BUY
$2.61 - $5.21 $300 - $599
115 Added 0.09%
126,260 $486,000
Q4 2019

Feb 05, 2020

BUY
$3.67 - $5.7 $2,763 - $4,292
753 Added 0.6%
126,145 $473,000
Q3 2019

Oct 23, 2019

SELL
$3.89 - $7.43 $3,073 - $5,869
-790 Reduced 0.63%
125,392 $666,000
Q2 2019

Aug 14, 2019

BUY
$2.7 - $6.11 $7,929 - $17,945
2,937 Added 2.38%
126,182 $485,000
Q1 2019

May 01, 2019

SELL
$2.11 - $5.33 $7,287 - $18,409
-3,454 Reduced 2.73%
123,245 $629,000
Q4 2018

Jan 31, 2019

BUY
$1.92 - $3.62 $81,022 - $152,760
42,199 Added 49.94%
126,699 $243,000
Q3 2018

Nov 07, 2018

SELL
$2.81 - $3.78 $17,492 - $23,530
-6,225 Reduced 6.86%
84,500 $319,000
Q2 2018

Aug 06, 2018

BUY
$2.26 - $3.84 $52,845 - $89,790
23,383 Added 34.72%
90,725 $283,000
Q1 2018

May 02, 2018

BUY
$2.39 - $4.01 $11,531 - $19,348
4,825 Added 7.72%
67,342 $161,000
Q4 2017

Feb 09, 2018

SELL
$2.51 - $4.4 $35,840 - $62,827
-14,279 Reduced 18.59%
62,517 $244,000
Q3 2017

Nov 06, 2017

BUY
$2.4 - $2.94 $184,310 - $225,780
76,796
76,796 $194,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.22B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.